Treatment of visceral leishmaniasis: Pitfalls and stewardship

Dorlo, Thomas P.C.; Ostyn, Bart A.; Uranw, Surendra; Dujardin, Jean-Claude; Boelaert, Marleen

doi:https://doi.org/10.1016/S1473-3099(16)30091-3

Treatment of visceral leishmaniasis: Pitfalls and stewardship

DSpace/Manakin Repository

Treatment of visceral leishmaniasis: Pitfalls and stewardship

Dorlo, Thomas P.C.; Ostyn, Bart A.; Uranw, Surendra; Dujardin, Jean-Claude; Boelaert, Marleen

(2016) The Lancet Infectious Diseases, volume 16, issue 7, pp. 777 - 778

(Letter)

Download/Full Text

An Open Access version of this item is not available due to the copyright policy of the publisher.

Keywords: amphotericin B lipid complex, miltefosine, alternative medicine, antibiotic resistance, bioequivalence, drug combination, disease elimination, drug efficacy, elimination half-life, human, Leishmania donovani, letter, monotherapy, priority journal, teratogenicity, treatment planning, visceral leishmaniasis

DOI: https://doi.org/10.1016/S1473-3099(16)30091-3

ISSN: 1473-3099

Publisher: Lancet Publishing Group

(Non peer reviewed)

See more statistics about this item